Mycophenolate Sodium: Clinical Trials

14 trials of Mycophenolate Sodium, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 1 withdrawn. 14 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 414Completed 13, Withdrawn 1

Follow Mycophenolate Sodium: new trials by email Literature Review of Mycophenolate Sodium trials Research Report on Mycophenolate Sodium

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation
Sirolimus, Everolimus, Mycophenolic acid - Kidney Transplant Infection
Phase 4CompletedHospital do Rim e Hipertensão12092017-06-182023-04-24
Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients
Tacrolimus Extended Release Capsule, Mycophenolate mofetil, Prednisone - Immunosuppression
Phase 4CompletedMedical University of South Carolina252017-05-052019-12-26
Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring
Myfortic®, Neoral®, Cellcept® - Cardiovascular Disease, Cardiovascular Outcomes
Phase 4WithdrawnUniversity of Saskatchewan2014-02-012017-01-09
Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients
sirolimus, tacrolimus, mycophenolate - Disorder Related to Renal Transplantation, Cytomegalovirus Infections
Phase 4CompletedAssociação Médico Espírita de Botucatu482014-01-012016-02-17
A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)
Mycophenolate sodium, Mycophenolate mofetil - Renal Transplantation
Phase 4CompletedIrmandade Santa Casa de Misericórdia de Porto Alegre1002013-04-012015-04-03
Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS
Mycophenolate sodium, Pantoprazole, Mycophenolate mofetil - Transplantation, Immunosuppression
Phase 4CompletedKlemens Budde202012-01-012019-02-21
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
Thymoglobulin, Everolimus, Basiliximabe - Cytomegalovirus Infection, Renal Transplant Failure
Phase 4CompletedHospital do Rim e Hipertensão3002011-05-012015-03-23
Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation
Basiliximab, Tacrolimus, Mycophenolic Acid - Liver Transplantation
Phase 4CompletedUniversity of California, Los Angeles592011-01-012022-09-29
Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study
Myfortic plus low-dose steroid, Prednisolone - Nephrosis, Lipoid
Phase 4CompletedThe University of Hong Kong202010-09-012018-06-01
A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients
MMF, EC-MPS, Prednisone - Kidney Transplantation
Phase 4CompletedHoffmann-La Roche232009-11-012015-08-27
A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients
Prograf, Advagraf, Myfortic - Liver Transplantation
Phase 4CompletedAstellas Pharma Inc442009-04-012016-01-29
Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant
Mycophenolate sodium - Kidney Transplantation
Phase 4CompletedNovartis182008-05-012017-02-23
Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State
Myfortic - Kidney Transplantation
Phase 4CompletedUniversity of Utah212007-12-012016-05-06
Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients
Mycophenolate Sodium - Gastrointestinal Symptoms, Heart Transplantation
Phase 4CompletedCedars-Sinai Medical Center112006-06-012020-07-30

Conditions studied

Cytomegalovirus Infections (2)  ·  Cardiovascular Diseases (1)  ·  Nephrosis, Lipoid (1)  ·  Rejection, Psychology (1)  ·  Renal Insufficiency (1)

Sponsors

Hospital do Rim e Hipertensão (2)  ·  Associação Médico Espírita de Botucatu (1)  ·  Astellas Pharma Inc (1)  ·  Cedars-Sinai Medical Center (1)  ·  Hoffmann-La Roche (1)  ·  Irmandade Santa Casa de Misericórdia de Porto Alegre (1)  ·  Klemens Budde (1)  ·  Medical University of South Carolina (1)  ·  Novartis (1)  ·  The University of Hong Kong (1)  ·  University of California, Los Angeles (1)  ·  University of Saskatchewan (1)  ·  University of Utah (1)

Countries

Brazil (4)  ·  United States (4)  ·  Germany (2)  ·  Canada (1)  ·  China (1)  ·  Taiwan (1)

Top investigators

Ahmed Shoker, MD (1)  ·  Bruna Cardoso, Pharmacist (1)  ·  Daniela Seelig, Physician (1)  ·  Elizete Keitel, Physician (1)  ·  Ernst Schwarz, MD (1)  ·  Fabiano Klaus, Physician (1)  ·  Fady M Kaldas, MD (1)  ·  Fuad Shihab, MD (1)  ·  Helen Zanetti, Pharmacist (1)  ·  James Fleming, PharmD (1)  ·  Klemens Budde, Prof Dr (1)  ·  Larissa Pacheco, Pharmacist (1)

Results publications

PMID 25988935, PMID 26398638, PMID 31769845, PMID 33988338, PMID 35230699, PMID 37525373

NIH funding

2009 (1)